Zevra Therapeutics (ZVRA) Total Current Liabilities (2014 - 2026)

Zevra Therapeutics has reported Total Current Liabilities for 13 years, with the latest figure at $47.0 million in Q1 2026.

• For the quarter ending Q1 2026, Total Current Liabilities rose 74.33% year-over-year to $47.0 million; the trailing twelve-month figure through Mar 2026 stood at $47.0 million (up 74.33% YoY), and the FY2025 full-year result was $39.3 million, up 15.3% from the prior year.
• Total Current Liabilities for Q1 2026 stood at $47.0 million, up from $39.3 million in the prior quarter.
• The five-year high for Total Current Liabilities was $73.7 million in Q4 2023, with the low at $48000.0 in Q2 2022.
• Historically, Total Current Liabilities has averaged $26.0 million across 5 years, with a median of $27.0 million in 2025.
• Annual changes were most pronounced in 2022 — Total Current Liabilities slumped 99.19% — and 2023, when it soared 37925.0%.
• Zevra Therapeutics' Total Current Liabilities stood at $12.0 million in 2022, then surged by 513.16% to $73.7 million in 2023, then plunged by 53.79% to $34.1 million in 2024, then grew by 15.3% to $39.3 million in 2025, then advanced by 19.73% to $47.0 million in 2026.
• The last three Total Current Liabilities figures came in at $47.0 million (Q1 2026), $39.3 million (Q4 2025), and $26.1 million (Q3 2025), per Business Quant data.